Valuation: Novacyt

Market Cap 3.09Cr 3.56Cr 2.87Cr 2.65Cr 4.99Cr 339.87Cr 5.08Cr 34Cr 13Cr 168.8Cr 13Cr 13Cr 567.65Cr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 3.29Cr 3.79Cr 3.05Cr 2.82Cr 5.3Cr 361.37Cr 5.4Cr 36Cr 14Cr 179.47Cr 14Cr 14Cr 603.55Cr EV / Sales 2026 *
1.08x
EV / Sales 2027 * 1.03x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
1 day-1.22%
1 week-7.83%
Current month+5.80%
1 month+5.80%
3 months+23.52%
Current year+2.96%
1 week 36
Extreme 36
39.5
1 month 33.5
Extreme 33.5
41.6
Current year 26.6
Extreme 26.6
86
1 year 26.6
Extreme 26.6
86
3 years 26.6
Extreme 26.6
137
5 years 26.6
Extreme 26.6
497.3
10 years 6.03
Extreme 6.03
1,270
Manager TitleAgeSince
Chief Executive Officer 53 01/05/2024
Director of Finance/CFO 44 01/01/2020
Chief Operating Officer - 01/11/2021
Director TitleAgeSince
Director/Board Member 75 03/07/2006
Director/Board Member 60 27/06/2017
Director/Board Member 44 02/01/2024
Change 5-day change 1-year change 3-year change Capi.($)
-1.22%-7.83% - - 3.61Cr
+0.95%+3.39%-34.51%-46.42% 63Cr
-9.49%-45.57%+71.26% - 32Cr
+4.31%+2.31%+13.68%+68.35% 9.67Cr
-0.81%-11.21%-47.97%-11.85% 9.64Cr
Average -1.25%-13.68%+0.61%+3.36% 28.62Cr
Weighted average by Cap. -1.83%-11.94%-1.84%-28.89%

Financials

2026 *2027 *
Net sales 3.05Cr 3.51Cr 2.83Cr 2.61Cr 4.92Cr 335.5Cr 5.01Cr 34Cr 13Cr 166.63Cr 13Cr 13Cr 560.36Cr 3.49Cr 4.01Cr 3.24Cr 2.99Cr 5.62Cr 383.16Cr 5.73Cr 38Cr 15Cr 190.3Cr 15Cr 15Cr 639.96Cr
Net income - -
Net Debt 19.56L 22.52L 18.16L 16.75L 31.55L 21Cr 32.13L 2.15Cr 84.2L 11Cr 84.57L 82.71L 36Cr 48.42L 55.74L 44.96L 41.47L 78.11L 53Cr 79.53L 5.32Cr 2.08Cr 26Cr 2.09Cr 2.05Cr 89Cr
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
216
Date Price Change Volume
30/26/30 GBX 36.50 -1.22% 4,791
29/26/29 GBX 36.95 +1.23% 50,638
28/26/28 GBX 36.50 -2.41% 61,038
27/26/27 GBX 37.40 -1.58% 12,647
24/26/24 GBX 38.00 -4.04% 61,636

Annual profits - Rate of surprise